Full Text View
Tabular View
No Study Results Posted
Related Studies
Connect to Protect Partnerships for Youth Prevention Interventions: Phase II
This study has been completed.
First Received: February 15, 2005   Last Updated: July 16, 2007   History of Changes
Sponsors and Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT00103896
  Purpose

This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such Adolescent Trials Network (ATN) research activities.

This phase will describe specific locations within high-risk areas where youth, ages 12-24, spend time. HIV risk behaviors, social networking patterns and HIV prevalence among youth at these venues will be assessed by administering anonymous computerized interviews to eligible and willing youth. This information will be shared with community partners during scheduled working group meetings.


Condition
HIV Infection

MedlinePlus related topics: AIDS
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title: Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II

Further study details as provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Estimated Enrollment: 1500
Study Start Date: September 2003
Estimated Study Completion Date: September 2006
Detailed Description:

This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such ATN research activities.

During this phase, each ATN site will gather additional information within high-risk areas and solicit community partner input to ultimately pinpoint the specific locations where at-risk youths, ages 12-24, may be recruited for interventions. This will be done by the following methods:

Venues will be identified by HIV+ youth at the ATN site by participation in an anonymous computerized interview. Site staff will then perform brief venue interviews (BVIs) at selected venues to assess the potential yield of youths 12-24 years old. Community partners will also provide the site staff with information on known high-risk venues. High-risk venues will further be identified by the results of anonymous computerized interviews and HIV assays obtained from eligible and willing youth participants at the venues. The interviews will gather information on HIV risk behaviors, social networking patterns and HIV prevalence among youths at these venues. This information will be shared with community partners during scheduled working group meetings.

  Eligibility

Ages Eligible for Study:   12 Years to 24 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Index Subjects:

  • Documented HIV-infection
  • Acquisition of HIV after age 9 years
  • Verbal confirmation of 12-24 years of age
  • Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months
  • Ability to understand and willingness to provide informed consent/assent

BVI subjects:

  • Youths who appear to be 12-24 years old

HIV Serosurvey subjects at the venues:

  • Verbal confirmation of 12-24 years of age
  • Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months
  • Ability to understand and willingness to provide informed consent/assent

Exclusion Criteria:

  • Visibly distraught and/or emotionally unstable (i.e. depressive mood, exhibiting manic, suicidal or violent behavior, etc.)
  • Visibly intoxicated or under the influence of psychoactive agents
  • Clinically presents as acutely ill
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00103896

Locations
United States, California
Childrens Hospital of Los Angeles
Los Angeles, California, United States, 90054
Univ of Califormia at San Francisco
San Francisco, California, United States, 94143
UCSD Mother, Child & Adolescent HIV Program
San Diego, California, United States, 92103
United States, District of Columbia
Children's Hospital National Medical Center
Washington, District of Columbia, United States, 20010
United States, Florida
USF Peds Div. of Infectious Disease
Tampa, Florida, United States, 33606
University of Miami
Miami, Florida, United States, 33101
Children's Diag. and Treatment Center
Ft. Lauderdale, Florida, United States, 33301
United States, Illinois
Stroger Hospital of Cook County
Chicago, Illinois, United States, 60612
United States, Louisiana
Tulane Medical Center
New Orleans, Louisiana, United States, 70112
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Childrens' Hospital of Boston
Boston, Massachusetts, United States, 02115
United States, New York
Montefiore Medical Center, Adolescent AIDS Program
Bronx, New York, United States, 10467
Mount Sinai Medical Center
New York, New York, United States, 10128
United States, Pennsylvania
Children's Hopsital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Puerto Rico
University Pediatric Hospital
San Juan, Puerto Rico, 00936
Sponsors and Collaborators
Investigators
Study Chair: Jonathan Ellen, MD Johns Hopkins Medical Center
Principal Investigator: Ligia Peralta, MD Division of Adolescent & Young Adult Medicine University of MD, Medical School
Principal Investigator: Donna Futterman, MD Montefiore Medical Center
Principal Investigator: Marvin Belzer, MD Childrens Hosp of Los Angeles, Division of Adolescent Medicine
Principal Investigator: Bret Rudy, MD Children's Hospital of Philadelphia
Principal Investigator: Larry D'Angelo, MD Children's Research Institute
Principal Investigator: Cathryn Samples, MD Children's Hospital Boston
Principal Investigator: Lisa Henry-Reid, MD John H. Stroger Jr. Hospital and the CORE Center
Principal Investigator: Ana Puga, MD Children’s Diag. and Treatment Ctr of Ft. Lauderdale, FL
Principal Investigator: Lawrence Friedman, MD University of Miami, School of Medicine, Div of Adolescent Medicine
Principal Investigator: Patricia Emmanuel, MD University of South Florida, Peds Div of Infectious Disease
Principal Investigator: Sue Ellen Abdalian, MD Tulane Medical Center
Principal Investigator: Linda Levin, MD Mount Sinai Adolescent Health Center
Principal Investigator: Irma Febo, MD University of Puerto Rico, Medical Sciences Campus
Principal Investigator: Stephen A Spector, MD UCSD Mother, Child, & Adolescent HIV Program
Principal Investigator: Rolando M Viani, MD UCSD Mother, Child, & Adolescent HIV Program
Principal Investigator: Barbara Moscicki, MD UCSF, Division of Adoles. Med
Principal Investigator: Coco Auerswald, MD UCSF, Division of Adoles. Med
  More Information

Additional Information:
No publications provided

Study ID Numbers: ATN 016b
Study First Received: February 15, 2005
Last Updated: July 16, 2007
ClinicalTrials.gov Identifier: NCT00103896     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
High-risk youth
HIV infected youth
Community mobilization
HIV serosurveys

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
Virus Diseases
Sexually Transmitted Diseases, Viral
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Infection
Retroviridae Infections
Immunologic Deficiency Syndromes

ClinicalTrials.gov processed this record on May 07, 2009